Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium
British Journal of Cancer, 08/03/2012
Clinical Article
Beer TM et al. – This study shows that first–line sagopilone has noteworthy anti–tumour activity and a clinically significant level of neuropathy for patients with metastatic chemotherapy–naïve castration–resistant prostate cancer (CRPC).



